U.S. Medical Marijuana Market Size By Application (Pain Management {Neuropathic Pain, Cancer Pain}, Muscle Spasms, Nausea, Anorexia, Seizures), By Route of Administration, (Inhalation, Oral, Topical), By Distribution Channel (Dispensaries, Online), Industry Analysis Report, Zonal Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

Industry Trends

U.S. Medical Marijuana Market size exceeded USD 7.2 billion in 2020 and is estimated to expand at a CAGR of 10.5% between 2021 and 2027. A significant contribution to the rapid growth witnessed by the market is the large-scale awareness surrounding the treatment of chronic diseases. The increasing awareness is primarily compelling the regulatory authorities to legalize medicinal use of marijuana. As of 2020, 34 states in the U.S. have approved and commercialised the sales of medical marijuana. However, use of cannabis is still identified as illegal at a federal level, limiting the overall market potential. However, a rise in R&D activities has led to the increasing market penetration of medical cannabis for various medical conditions including cancer, neurology, HIV/AIDS, muscle spasms, among others.
 

Get more details on this report - Request Free Sample PDF
 

Medical marijuana is the marijuana plant and its downstream products used for the treatment of several medical conditions. It is used to treat conditions such as nausea and pain management among others. Several states where the medicinal use of cannabis is considered illegal are noted to make the shift and decriminalize possession as well as cultivation. This represents an optimistic scenario for the market in the coming years.
 

The economic impact of COVID-19 pandemic on the U.S. medical marijuana market is observed to be optimistic across the country. A significant spike in the number of patients as well as prescription across states in U.S. has caused an upsurge in the market. However, as the legalization and commercialization of recreational cannabis gain momentum, states such as Colorado, California and Washington among others have showcased a sluggish performance of the industry. This is anticipated to create hurdles in the market growth over the coming years.
 

Increasing focus on R&D activities to study the impact on other medical disorders

Significant research activities in the initial years of commercialization have transformed the pain management segment into a highly mature segment of the market. This allows room for research activities to study the effectiveness of marijuana in other medical disorders. The approach is noted to be fruitful in the industry as several other applications such as HIV/AIDS, anxiety, among others have been considered and qualified by several states. Additionally, several government grants and funds are also allocated to explore additional uses of cannabis plants for medicinal purposes. Support from various government and non-government organizations for R&D activities of cannabis will be conducive to the market expansion.
 

Regulatory hurdles limit the market revenue

The growing interest in medical marijuana has led to its increasing use in treating medical conditions and related symptoms such as pain, depression, anxiety, multiple sclerosis, insomnia, arthritis, PTSD, nausea, among others. The qualifying conditions for medical marijuana vary across states in the U.S. In some cases, states such as California, Oklahoma and District of Columbia, among others, allow physician’s discretion when prescribing medical marijuana. However, on the other hand, several states allow prescriptions only for a limited set of qualifying conditions. As the drug is identified as illegal at a federal level, possessing medical marijuana while travelling across states is also considered illegal. Further, with several states yet to legalize its consumption, a proportion of the demand for cannabis in these states is poised to be fulfilled by the illegal means, or black market. This hampers the market, in particular, while also impacting the country’s economy to a certain extent. Cumulatively, these factors represent some of the grey areas of the industry, potentially slowing down the market value.
 

Pain management remains the dominant segment during the forecast timeframe

Get more details on this report - Request Free Sample PDF
 

The pain management segment in the U.S. medical marijuana market will capture more than 75% of the market share by 2027. The increasing prevalence of pain in U.S. is primarily contributing to the country’s growing demand for medical marijuana. According to the Centres for Disease Control and Prevention, the prevalence of chronic pain in U.S. is 20.4% of U.S. adults while the prevalence of high-impact chronic pain is 7.4% of U.S. adults. The rising prominence of medical cannabis as an alternative to traditional medicine is noted to significantly contribute towards the segment growth.
 

Relatively higher preference for inhalation route of administration increases the demand

 The inhalation segment accounted for over USD 5.3 billion in 2020. A controlled dose can be delivered via the inhalation route of administration, making it one of the preferred options. Patients preferring inhalation are noted to experience a faster relief as over 50% THC is delivered to the lungs.
 

Rising adoption of medical marijuana in hospitals is expected to augment the segment expansion

The U.S. medical marijuana market for dispensaries segment is predicted to observe a 10.3% growth rate by 2027. As each state is noted to run its own medical marijuana program, it engages dispensaries to deliver medical marijuana only to registered patients. The brick and mortar distribution model assist the authorities to monitor the sales as well as procurement of medical marijuana.
 

North East zone to register a high growth rate during the forecast period

Get more details on this report - Request Free Sample PDF
 

North East zone in the U.S. medical marijuana market is slated to expand at a CAGR of 13.6% through 207. Over 9 states in the North East have legalized the medicinal application of marijuana with Pennsylvania leading the revenue contribution in the region. With a relatively higher price of medical marijuana in the region owing to regulatory implications, the North East zone is anticipated to gradually expand over the forecast period.
 

Product launches and acquisitions are set to create lucrative growth opportunities for players operating in the market

Prominent leaders functioning in the market include Canopy Growth, Aurora Cannabis, Inc., Medical Marijuana, Inc., GW Pharmaceuticals, Aphria, Inc., Tilray, Emerald Health Therapeutics, and United Cannabis. A balanced pool of organic and inorganic growth strategies are observed across market participants. Companies are noted to adopt acquisition strategies in order to enhance their presence.
 

Some of the recent industry developments:

• In October 2019, Canopy Growth acquired a majority stake in Biosteel Sports Nutrition Inc., leading producer of sports nutrition products. The deal assists Canopy Growth to venture into sports and nutrition business segment. It also lays the foundation for the company to penetrate its CBD infused products in the future in U.S. market.
   
• In May 2019, Canopy Growth acquired a skincare company This Works for over USD 50 million. The acquisition enables the company to expand its product offerings as well as cater to a wider customer base.
   

The U.S. medical marijuana market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:
 

Market, By Application

• Pain Management
  • Neuropathic Pain
  • Cancer Pain
  • Others
• Muscle Spasms
• Nausea
• Anorexia
• Seizures
• Others

Market, By Route of Administration

• Inhalation
• Oral
• Topical

Market, By Distribution Channel

• Dispensaries
• Online

The above information is provided for the following zones and states:

• North East
  • Connecticut
  • Maine
  • Massachusetts
  • New Hampshire
  • Rhode Island
  • Vermont
  • New Jersey
  • New York
  • Pennsylvania
• North East Central
  • Illinois
  • Michigan
• West South Central
  • Ohio
  • Arkansas
  • Oklahoma
  • Louisiana
• South Atlantic
  • Delaware
  • Florida
  • Maryland
  • Washington DC
• West North Central
  • Minnesota
  • North Dakota
  • Missouri
  • Iowa
• Pacific Central
  • Alaska
  • California
  • Hawaii
  • Oregon
  • Washington
• Mountain States
  • Arizona
  • Colorado
  • Nevada
  • New Arkansas
  • Montana
  • Utah